Linaget M OD 1000mg/5mg Tablet

Introduction

Linaget M OD is a prescription medication that contains the active ingredients Metformin and Linagliptin. It is available in tablet form and is primarily used to treat type 2 diabetes.

Uses

Linaget M OD is prescribed to help control blood sugar levels in individuals with type 2 diabetes. It is used alongside a healthy diet and exercise program to improve glycemic control and prevent complications associated with diabetes.

Dosage and Administration

The dosage of Linaget M OD may vary depending on individual needs and medical history. Follow the instructions provided by your healthcare professional. Generally, the recommended starting dose is one tablet taken orally once daily with meals. Your doctor may adjust the dosage as needed to achieve the desired blood sugar control.

Mechanism of Action

Linaget M OD contains two active ingredients: Metformin and Linagliptin. Metformin works by reducing the production of glucose in the liver and increasing the sensitivity of muscle cells to insulin. Linagliptin, on the other hand, helps increase the production of insulin in response to high blood sugar levels. Together, these medications help improve glycemic control in individuals with type 2 diabetes.

Side Effects

Common side effects may include nausea, diarrhea, stomach upset, and headache. These side effects are usually mild and go away on their own. However, if they persist or become bothersome. Consult your healthcare professional.

In rare cases, Linaget M OD may cause serious side effects such as lactic acidosis, a rare but potentially life-threatening condition. Symptoms of lactic acidosis include rapid breathing, muscle pain, weakness, and feeling cold or dizzy. If you experience any of these symptoms, seek immediate medical attention.

Drug Interactions

Linaget M OD may interact with other medications, including certain antibiotics, antifungal drugs, and medications used to treat high blood pressure. Inform your healthcare professional about all the medications you are taking, including over-the-counter drugs and herbal supplements, to avoid potential drug interactions.

Precautions

Before taking Linaget M OD, inform your healthcare professional about any medical conditions you have, especially if you have kidney or liver problems. This medication may not be suitable for individuals with certain medical conditions or those who are allergic to Metformin or Linagliptin.

Linaget M OD may also interact with alcohol, so it is advisable to limit or avoid alcohol consumption while using this medication.

Storage

Linaget M OD should be stored at room temperature, away from moisture and heat. Keep the medication in its original packaging and out of reach of children.

Patient Tips

• Take Linaget M OD with meals to reduce the risk of stomach upset.
• Follow a balanced diet and exercise regularly as recommended by your healthcare professional.
• Monitor your blood sugar levels regularly and report any significant changes or concerns to your doctor.
• Attend regular check-ups to assess the effectiveness of the medication and make any necessary dosage adjustments.
• Carry a form of identification or wear a medical alert bracelet indicating that you are taking Linaget M OD in case of emergencies.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Linagliptin: medicine to treat type 2 diabetes (NHS UK) [Accessed 10 Jun. 2024] (online) Available at:
• Glyxambi 10 mg/5 mg Film-coated Tablets (Health Professionals SmPC) Available at:
• Linagliptin (Drugs.com) [Accessed 15 Jun. 2024] (online) Available at:
• linagliptin (RX) [Accessed 5 Jun. 2024] (online) Available at:
• Linagliptin (MedlinePlus) [Accessed 4 Jun. 2024] (online) Available at:
• Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. [Accessed 20 Jun. 2024] Available at: